Edwards Lifesciences Corp (EW)vsLivaNova PLC (LIVN)
EW
Edwards Lifesciences Corp
$84.37
-2.77%
HEALTHCARE · Cap: $49.99B
LIVN
LivaNova PLC
$78.18
0.00%
HEALTHCARE · Cap: $4.50B
Smart Verdict
WallStSmart Research — data-driven comparison
Edwards Lifesciences Corp generates 343% more annual revenue ($6.51B vs $1.47B). EW leads profitability with a 15.4% profit margin vs 12.8%. LIVN appears more attractively valued with a PEG of 0.93. LIVN earns a higher WallStSmart Score of 68/100 (B-).
EW
Buy55
out of 100
Grade: C
LIVN
Strong Buy68
out of 100
Grade: B-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+68.9%
Fair Value
$254.99
Current Price
$84.37
$170.62 discount
Margin of Safety
+7.7%
Fair Value
$71.98
Current Price
$78.18
$6.20 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Strong operational efficiency at 29.8%
Earnings expanding 287.8% YoY
Conservative balance sheet, low leverage
Growing faster than its price suggests
Areas to Watch
Expensive relative to growth rate
Weak financial health signals
Premium valuation, high expectations priced in
Earnings declined 25.4%
Distress zone — elevated risk
Comparative Analysis Report
WallStSmart ResearchBull Case : EW
The strongest argument for EW centers on Debt/Equity, Altman Z-Score, Operating Margin. Profitability is solid with margins at 15.4% and operating margin at 29.8%. Revenue growth of 13.6% demonstrates continued momentum.
Bull Case : LIVN
The strongest argument for LIVN centers on EPS Growth, Debt/Equity, PEG Ratio. Revenue growth of 10.8% demonstrates continued momentum. PEG of 0.93 suggests the stock is reasonably priced for its growth.
Bear Case : EW
The primary concerns for EW are PEG Ratio, Piotroski F-Score, P/E Ratio. A P/E of 51.6x leaves little room for execution misses.
Bear Case : LIVN
The primary concerns for LIVN are Altman Z-Score.
Key Dynamics to Monitor
EW profiles as a mature stock while LIVN is a value play — different risk/reward profiles.
LIVN carries more volatility with a beta of 0.87 — expect wider price swings.
EW is growing revenue faster at 13.6% — sustainability is the question.
EW generates stronger free cash flow (585M), providing more financial flexibility.
Bottom Line
LIVN scores higher overall (68/100 vs 55/100) and 10.8% revenue growth. EW offers better value entry with a 68.9% margin of safety. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Edwards Lifesciences Corp
HEALTHCARE · MEDICAL DEVICES · USA
Edwards Lifesciences is an American medical technology company headquartered in Irvine, California, specializing in artificial heart valves and hemodynamic monitoring.
Visit Website →LivaNova PLC
HEALTHCARE · MEDICAL DEVICES · USA
LivaNova PLC, a medical device company, designs, develops, manufactures and sells therapeutic solutions globally. The company is headquartered in London, the United Kingdom.
Visit Website →Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?